pharma · Adolescent Patients (13 to 17 years of age) with Schizophrenia · Adolescent patient (13-17 years of age) with Schizophrenia
Gedeon Richter
Gedeon Richter Plc.
Gedeon Richter is a pharma organization headquartered in Budapest, EU. Primary therapeutic focus areas include Adolescent Patients (13 to 17 years of age) with Schizophrenia, Adolescent patient (13-17 years of age) with
Budapest, EU HQ
2,763 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Budapest, EU
- Employees
- 2,763
- Programs
- 2
- Drugs
- 5
- Patents
- 0
RGH-MD-20
Phase 3 · small molecule · Adolescent Patients (13 to 17 years of age) with Schizophrenia
RGH-MD-20 for Adolescent Patients (13 to 17 years of age) with Schizophrenia is a Phase 3 program (small_molecule) at Gedeon Richter Plc. with 1 ClinicalTrials.gov record(s).
Internal code RGH-MD-20
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Gedeon Richter Plc.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Adolescent Patients (13 to 17 years of age) with Schizophrenia
- Status
- active
- Trials
- 1